Telix's ProstACT Study Data Earns Late-Breaking Spot at ASCO 2026 — Telix Pharmaceuticals Limited

Event summary

Safety and tolerability data from Part 1 of Telix's ProstACT Global Phase 3 trial will be presented as a late-breaking oral presentation at ASCO 2026.
The study evaluates TLX591-Tx, a PSMA-targeted lutetium radio antibody-drug conjugate, in combination with standard of care for mCRPC patients.
Part 1 of the trial involved 36 patients and assessed tolerability, biodistribution, and radiation dose profile.
The presentation is scheduled for June 1, 2026, during the Clinical Science Symposium at ASCO.

The big picture

Telix's inclusion in the late-breaking abstracts at ASCO underscores the growing interest in next-generation radiopharmaceutical therapies for prostate cancer. The ProstACT Global study is part of a broader trend towards targeted therapies that aim to reduce toxicity and improve patient outcomes. Telix's focus on leveraging antibody-drug conjugates with different targeting mechanisms positions it competitively in the evolving oncology treatment landscape.

What we're watching

Clinical Efficacy: How the safety and tolerability data from Part 1 will influence the perception of TLX591-Tx's potential in the prostate cancer treatment landscape.
Regulatory Pathway: Whether the positive data presentation at ASCO will accelerate regulatory approvals for TLX591-Tx.
Market Positioning: The pace at which Telix can differentiate TLX591-Tx from existing PSMA-targeted therapies based on its unique pharmacology and safety profile.